Phychem Technologies Limited reports 86.99% family ownership

Phychem Technologies Limited reported 86.99% family ownership through four promoter-directors holding 65,59,154 equity shares and occupying four of its six board seats as of the Red Herring Prospectus. The other two seats were held by independent directors, neither of whom owned shares in Phychem.

How concentrated is Phychem’s 86.99% family ownership?

Phychem’s ownership is concentrated in four related promoter-directors who held 65,59,154 equity shares, or 86.99% of the company’s equity, as of the Red Herring Prospectus. Phychem had 26 shareholders at that date, placing the disclosed family holding across a shareholder base of 26 investors.

Umakant Nivrutti Savadekar held the largest individual stake at 37,18,633 shares, or 49.32% of Phychem’s equity. Ulka Umakant Savadekar held 25,38,999 shares, or 33.67%; Nivrutti Sonu Savdekar held 2,26,122 shares, or 3.00%; and Vijaya Nivrutti Savdekar held 75,400 shares, or 1.00%.

Phychem’s concentration results from the four promoters also serving as directors, rather than from a dispersed group of non-board shareholders. The reported allocation would remain unchanged unless the four holders sell, acquire or otherwise transfer shares; the prospectus disclosed no subsisting shareholder agreements and no strategic or financial partners, except as disclosed in the document.

Who occupies Phychem’s four family board seats?

Phychem’s four family board seats are held by Umakant, Ulka, Nivrutti and Vijaya. The prospectus identifies the four as relatives under Section 2(77) of the Companies Act, 2013: Umakant is Ulka’s husband and the son of Nivrutti and Vijaya, who are married to each other.

Umakant has served on Phychem’s board since its incorporation on June 13, 2013 and was redesignated chairman and managing director on August 30, 2025. His three-year term began on August 30, 2025, and his disclosed responsibilities cover manufacturing operations, procurement, sales and marketing; he reported around 21 years of rotational moulding industry experience.

Ulka has also been a director since June 13, 2013 and was redesignated whole-time director and chief financial officer, or CFO, on August 30, 2025. Her three-year term runs to August 30, 2028 and her stated responsibilities are finance and compliance. Nivrutti and Vijaya were directors from June 13, 2013 and became non-executive directors on August 30, 2025, with three-year terms subject to retirement by rotation.

The August 30, 2025 redesignations changed titles and the stated governance structure but left the family with four of the six board seats. Phychem converted from a private limited company to a public limited company on August 2, 2025 and adopted new articles of association on August 30, 2025.

How does Phychem’s board combine family seats and independence?

Phychem’s six-member board comprises two executive directors, two non-executive directors and two independent directors, leaving the promoter family with four seats and independent directors with two. The board includes one woman executive director, one woman non-executive director and one woman independent director, according to the corporate-governance disclosure.

Charmi Monil Shah and Rajendra Hunajirao Talele are Phychem’s two independent directors, and neither held equity shares as of the Red Herring Prospectus. Shah reported around 12 years of accounts and finance experience, while Talele reported around 31 years in pharmaceutical and drug development and began a five-consecutive-year term effective August 30, 2025 without retirement by rotation.

One independent-director appointment changed during the disclosed three-year board history. Niranjan Ramakant Kolhe was appointed on August 30, 2025 and ceased on July 18, 2026, when Shah was appointed; the board therefore retained two independent-director seats while one officeholder changed.

Phychem states that its board and committees comply with the corporate-governance requirements under the Companies Act, 2013 and Securities and Exchange Board of India, or SEBI, Listing Regulations. The SEBI Listing Regulations apply immediately upon listing of Phychem’s equity shares, but those requirements do not change the disclosed four-to-two split between family and independent board seats.

What oversight do Phychem’s board committees provide?

Phychem’s Audit Committee has two independent directors and one promoter executive, giving independent directors two of its three seats. Reconstituted by a board resolution dated July 20, 2026, the committee comprises Shah as chairperson, Talele as member and Umakant as member.

The Audit Committee must meet at least four times annually, with no more than 120 days between two meetings. Its quorum is two members or one-third of its membership, whichever is higher, and two independent directors must be present at each meeting. Its remit includes financial reporting, auditor oversight, related-party transaction approval, internal financial controls, risk-management systems and monitoring the use of proposed initial public offer funds.

Phychem’s Nomination and Remuneration Committee was also reconstituted on July 20, 2026. Shah chairs the three-member committee, Talele is a member and Nivrutti is its non-executive director member, giving the two independent directors two seats on that committee as well.

The committee arrangements sit alongside board authority and disclosed director interests. A special resolution passed at the August 30, 2025 extraordinary general meeting authorised borrowings up to Rs 100 crore in outstanding principal amount, excluding temporary bank loans in the ordinary course. The prospectus also identifies a November 6, 2015 lease of Phychem’s registered office from Ulka, its whole-time director and CFO.

Conclusion

Phychem combines an 86.99% promoter-family equity holding with a six-member board in which the same family holds four seats. The two independent directors hold no Phychem shares, but each has a seat on the three-member Audit Committee and Nomination and Remuneration Committee, where independent directors form a two-member majority.

The next governance measure to watch is Phychem’s stated plan to comply with SEBI Listing Regulations immediately upon listing. The July 20, 2026 committee reconstitutions require the Audit Committee to meet at least four times a year with two independent directors present, while any future share transfer could change the reported 86.99% promoter-director holding.